- Nwanaji-Enwerem, Jamaji C;
- Chung, Felicia Fei-Lei;
- Van der Laan, Lars;
- Novoloaca, Alexei;
- Cuenin, Cyrille;
- Johansson, Harriet;
- Bonanni, Bernardo;
- Hubbard, Alan E;
- Smith, Martyn T;
- Hartman, Sheri J;
- Cardenas, Andres;
- Sears, Dorothy D;
- Herceg, Zdenko
Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied. We performed a post-hoc analysis of a randomized controlled trial among overweight/obese breast cancer survivors (N = 192) assigned to metformin, placebo, weight loss with metformin, or weight loss with placebo interventions for 6 months. Epigenetic age was correlated with chronological age (r = 0.20-0.86; P < 0.005). However, no significant epigenetic aging associations were observed by intervention arms. Consistent with published reports in non-cancer patients, 6 months of metformin therapy may be inadequate to observe expected epigenetic age deceleration. Longer duration studies are needed to better characterize these relationships.Trial Registration: Registry Name: ClincialTrials.Gov.Registration Number: NCT01302379.Date of Registration: February 2011.URL: https://clinicaltrials.gov/ct2/show/NCT01302379.